Prostate Cancer is a type of malignancy, occurs in the prostate gland that is a part of male reproductive system.
&nbsp;
Prostate Cancer Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Prostate Cancer in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Prevalent Cases of Prostate Cancer</li>
<li>Total Diagnosed Cases of Prostate Cancer</li>
<li>Total Diagnosed Cases of Prostate Cancer patients by Clinical Stages</li>
<li>Prostate cancer cases by clinical stages &ndash;</li>
</ul>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Localized/ locally advanced cases (Stage I-III)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Biochemical recurrence/ progressive cases
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Metastatic cases
<ul>
<li>Age Group-specific Cases of Prostate Cancer &ndash;</li>
</ul>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&le; 54 years;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*55-64 years;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*65-74 years;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*75-84 years;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&gt;84 years
<ul>
<li>Prostate Cancer cases by Non-Metastatic CSPC/ CRPC and metastatic CSPC/ CRPC -</li>
</ul>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Non-metastatic castrate-sensitive prostate cancer (nmCSPC*/ nmHSPC*)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Non-metastatic castrate-resistant prostate cancer (nmCRPC*)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Metastatic castrate-sensitive prostate cancer (mCSPC/ mHSPC)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Metastatic castrate-resistant prostate cancer (mCRPC)
<ul>
<li>Total Treated Cases of mHSPC/CSPC and CRPC</li>
<li>Total Treated cases of Non-Metastatic CSPC/HSPC and CRPC&nbsp;&nbsp;</li>
</ul>
* Hormone-Sensitive Prostate Cancer (HSPC)
* Castrate-Resistant Prostate Cancer (CRPC)
* Castrate-Sensitive Prostate Cancer (CSPC)
&nbsp;
<a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/report-store/prostate-cancer-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Prostate Cancer Epidemiology</a>&nbsp;
<ul>
<li>Total Prevalent cases of Prostate Cancer in 7MM in 2020 were7,494,882</li>
<li>Total Prevalent cases of Prostate Cancer in the United States in 2020 were 3,478,728</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/report-store/prostate-cancer-market" target="_blank" rel="noopener noreferrer">Prostate Cancer Market</a>
The Market Size of Prostate Cancer is growing at 8.1% CAGR for the study period of 2017 to 2030.
&nbsp;
Prostate Cancer Market Drivers
<ul>
<li>Increasing Use of Biomarker Testing</li>
<li>Rising Geriatric Population and High Prevalence Rate of Prostate Cancer</li>
<li>Surge in Awareness regarding the Treatment of Prostate Cancer</li>
<li>Increase in Demand for Prostate Cancer Treatment Products</li>
</ul>
&nbsp;
Prostate Cancer Market Barriers
<ul>
<li>The complex issue of companion diagnostics</li>
<li>Cost Constraints&nbsp;</li>
<li>Entry Barrier</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight" target="_blank" rel="noopener noreferrer">Prostate Cancer Emerging Drugs</a>
The emerging drugs of the Prostate Cancer market are&nbsp;
<ul>
<li>Lynparza (Olaparib)</li>
<li>Opdivo (nivolumab)</li>
<li>177Lu-PSMA-617</li>
<li>Relugolix</li>
<li>HC-1119</li>
<li>Seviteronel (VT-464)</li>
<li>PROSTVAC-V/F</li>
<li>ODM-208</li>
<li>Sacituzumab Govitecan (IMMU-132)</li>
<li>Keytruda (Pembrolizumab/MK-3475)</li>
<li>Ipatasertib (RG7440)</li>
<li>Talazoparib</li>
<li>Capivasertib (AZD5363): AZD4635</li>
<li>PRX302 (topsalysin): Pamiparib (BGB-290)</li>
<li>Enoblituzumab (MGA271)</li>
<li>Tisotumab Vedotin</li>
<li>Dupilumab</li>
<li>Rubraca (Rucaparib)</li>
<li>Niraparib</li>
<li>Proxalutamide (GT0918)</li>
<li>Abemaciclib (LY2835219)</li>
<li>Tomivosertib (eFT508)</li>
<li>Onvansertib</li>
<li>RV001V</li>
<li>ProstAtak</li>
</ul>
And many others.&nbsp;&nbsp;
&nbsp;
Prostate Cancer Key Players
The key players in the Prostate Cancer market are
<ul>
<li>AstraZeneca</li>
<li>Merck Sharp &amp; Dohme</li>
<li>Bristol-Myers Squibb</li>
<li>Novartis</li>
<li>Myovant Sciences</li>
<li>Takeda</li>
<li>Hinova Pharmaceuticals</li>
<li>Innocrin Pharmaceutical</li>
<li>Bavarian Nordic</li>
<li>Orion Pharma</li>
<li>Immunomedics</li>
<li>Hoffmann-La Roche</li>
<li>Pfizer</li>
<li>Astellas Pharma</li>
<li>Sophiris Bio</li>
<li>BeiGene</li>
<li>MacroGenics</li>
<li>Genmab</li>
<li>Regeneron Pharmaceuticals</li>
<li>Clovis Oncology</li>
<li>Janssen Research &amp; Development</li>
<li>Suzhou Kintor Pharmaceutical</li>
<li>Eli Lilly and Company</li>
<li>eFFECTOR Therapeutics</li>
<li>Trovagene</li>
<li>RhoVacz</li>
<li>Advantagene</li>
</ul>
And many others.&nbsp;
&nbsp;
Stay tuned for latest updates on <a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/whitepaper-newsletter/prostate-cancer-market" target="_blank" rel="noopener noreferrer">Prostate Cancer treatment landscape</a>

Prostate cancer Market

Prostate cancer Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.